NHS Expands 'Fat Jab' Access to Millions

The NHS is set to significantly expand access to weight-loss injections, with the drug Wegovy (semaglutide) becoming available for individuals who are overweight and have a history of cardiovascular events. This new guidance from NICE recommends the drug for anyone with a BMI of 27 or higher who has experienced a heart attack, stroke, or has peripheral artery disease. Approximately 1.2 million people in England are estimated to fit these criteria, with prescriptions expected to begin in early August.

This broadened eligibility marks a major medical breakthrough, positioning these jabs as potentially as transformative as statins in managing heart health. Studies show semaglutide can reduce the risk of major cardiovascular events by 20%, regardless of weight loss. This contrasts with current, more stringent NHS criteria for accessing such medications, which have seen limited availability despite high demand.

While Mounjaro (tirzepatide) was introduced for weight loss more recently, Wegovy's expanded use targets a population with existing heart conditions, offering a dual benefit. Experts anticipate widespread use could alleviate the obesity crisis, reduce sick days, boost the economy, and lower rates of cancer, heart disease, and dementia.

However, the rollout faces challenges, with capacity limitations in GP surgeries and a lengthy timeline to treat all eligible patients. Many are already seeking these drugs privately due to high demand and restricted NHS access. Regulatory bodies are implementing stricter rules for private pharmacies to ensure patient safety amidst concerns over unregulated sales and severe side effects.